Dublin-listed Open Orphan has won a £4.3m (€4.7m) contract to conduct a human viral challenge study.
The contract is with one of the global top 10 vaccine companies.
This trial will be conducted in the company’s dedicated human viral challenge quarantine unit in London. The facility is Europe’s only commercial 24-bedroom quarantine clinic with on-site virology laboratory, according to a statement from the company.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).